The impact of side effects on long-term retention in three new antiepileptic drugs  by Bootsma, Hans P. et al.
Seizure 18 (2009) 327–331The impact of side effects on long-term retention in three new antiepileptic drugs
Hans P. Bootsma a,*, Lukas Ricker a, Yechiel A. Hekster c, Jacques Hulsman a, Danielle Lambrechts a,
Marian Majoie a, Ad Schellekens a, Marc de Kromb, Albert P. Aldenkamp a,b
aDepartments of Neurology, Clinical Neurophysiology, Neuropsychology and Pharmacology of the Epilepsy Centre Kempenhaeghe, Heeze, The Netherlands
bDepartment of Neurology, University Hospital of Maastricht, The Netherlands
cDepartment of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, The Netherlands
A R T I C L E I N F O
Article history:
Received 30 June 2008
Received in revised form 17 November 2008
Accepted 20 November 2008
Keywords:
Lamotrigine
Levetiracetam
Topiramate
Long-term retention
Side-effects of AEDs
Antiepileptics
Cognitive function
A B S T R A C T
Objective: To determine long-term retention, percentage of patients withdrawing because of adverse
events, percentage of patients achieving seizure freedom, safety proﬁle of the new anti-epileptic drugs
lamotrigine, levetiracetam and topiramate.
Methods: All patients treated with lamotrigine, levetiracetam or topiramate in the Epilepsy Centre were
identiﬁed. Each drug was analyzed from introduction of the drug in the Netherlands up to a ﬁnal
assessment point 2 years later.
Results: Data from 1066 patients were included: 336 for lamotrigine, 301 for levetiracetam, 429 for
topiramate. Two-year retention rates were 69.2% (lamotrigine), 45.8% (levetiracetam), 38.3%
(topiramate); (LTG vs. LEV at p < 0.001; LTG vs. TPM at p < 0.001; LEV vs. TPM at p = 0.005). Seizure
freedom rates were lowest for lamotrigine and highest for levetiracetam. Adverse events played a role in
drug discontinuation in 154/429 patients (35.9%) on topiramate, 52/336 patients (15.5%) on lamotrigine
(p < 0.001), 68/301 patients (22.5%) on levetiracetam (p < 0.001). Mood and general CNS-effects are
common in patients on lamotrigine and levetiracetam, and neurocognitive side effects are most
prevalent in patients on topiramate. A positive effect on cognition is frequently noted in patients on
lamotrigine.
Conclusion: A drug that is only modestly efﬁcacious but has a favourable safety proﬁle may look better
than a drug that is more efﬁcacious but produces clinically meaningful adverse events. Therefore, a
drug’s retention rate is mainly determined by its side effect proﬁle. As a consequence, retention rate was
highest for lamotrigine and lowest for topiramate. Intermediate retention rates were seen with
levetiracetam use.
 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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The primary goals of antiepileptic drug (AED) treatment are to
achieve complete seizure freedom, ideally without adverse events,
reduce morbidity, mortality, and seizure-related accidents, and
improve quality of life.1 In two-thirds of the patients with epilepsy
these goals are feasible with optimum AED therapy. For the
remaining one-third of patients with refractory epilepsies these
goals are not reached with existing AEDs and, the introduction of
several new AEDs in the recent past might be a welcome
development for improved patient treatment. Some studies2,3
have shown results of treatment changes in an apparent refractory
population.* Corresponding author at: Department of Pharmacology, Epilepsy Centre
Kempenhaeghe, P.O. Box: 61, NL-5590 A.B. Heeze, The Netherlands.
E-mail addresses: BootsmaHP@kempenhaeghe.nl, H.Bootsma@st-anna.nl,
a.aldenkamp5@chello.nl (H.P. Bootsma).
1059-1311/$ – see front matter  2008 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2008.11.006With a growing number of AEDs, it becomes more difﬁcult for
clinicians to make a rational choice which drug to prescribe for
which patient. To date, treatment of epilepsy is rather more
empirical than evidence-based.1 In an ideal situation, treatment
guidelineswill use information from largemulticentre randomized
controlled trials that compare AEDs in a head to head fashion.
These trials are however rarely performed. In the absence of such
trials, other methods must be used to compare new AEDs on their
intrinsic properties. The relevance of ﬁndings derived from meta-
analyses to clinical practice is limited. Studies included in meta-
analyses are typically of short duration among other limitations,4
whereas epilepsy is a chronic condition. Therefore, long-term open
label observational studies and clinical practice audits better
reﬂect everyday clinical practice regarding long-term efﬁcacy and
safety issues.5
One way to compare the long-term performances of AEDs in
clinical practice is to evaluate retention rates. Prolonged retention
of patients on their AED therapy is now accepted as one of the
clearest reﬂections of therapeutic efﬁciency and represents avier Ltd. All rights reserved.
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safety over time.6 Retention-time studies are especially useful
when the actual seizure-frequency reduction per patient and the
percentage of seizure-free patients are determined.7 Presently, it is
not clear whether efﬁcacy and safety contribute equally to the
retention rate of newAEDs. One studymentions that retention rate
may reﬂect more of AED tolerability rather than efﬁcacy.8
This audit focuses on the three most commonly prescribed new
AEDs in patients with refractory epilepsies in a tertiary referral
centre for epilepsy: lamotrigine (LTG), levetiracetam (LEV) and
topiramate (TPM). Our objectives were to compare the long-term
retention, the percentage of patients withdrawing because of
adverse events, the percentage of patients achieving seizure
freedom, and the safety proﬁle of LTG, LEV and TPM.
2. Methods
The study was approved by the Institutional Medical Ethics
Committee. All in- and out-patients who had been treated with
LTG, LEV or TPM in a certain period in the Epilepsy Centre
Kempenhaeghe were identiﬁed by means of our automated
medical information system (MIS) and subsequently analyzed.
Each drug was analyzed from the introduction of the drug in the
Netherlands up to a ﬁnal assessment point (TPM 1993–2002; LTG
1996–1997; LEV 2001–2003). Patients who had the drug of
interest prescribed initially elsewhere were not included to avoid
survival bias. Retention times were calculated from the time the
patients started to take the drug of interest to the time they
discontinued treatment, with a maximum follow-up period of 24
months. Data from patients who were still taking the drug at the
time of data collection were counted as censored data.
A standardized data form was developed. The data were
obtained from our Medical Information System and individual
patient medical records. Epilepsy and seizures were classiﬁedTable 1
Patient demographics and characteristics.
LTG
Total no. of patients 336
Age 32.8 
Age range 1–74
Age distribution 20.8% <
Sex (F/M) 170/16
Weight (kg) 63.3 
Type of epilepsy
Localization related 231 (68
Generalized 63 (18.
Undetermined 8 (2.4%
Not classiﬁed 34 (10.
Seizure type
Partial onset 272 (81
Generalized 182 (54
Not classiﬁed 21 (6.3
Nonepileptic attacks 36 (10.
Age at onset of seizures 11.0 
Duration of epilepsy before drug introduction (years) 22.0 
No. of mentally retarded 102 (30
CT abnormalities 19.0%
MRI abnormalities 25.0%
No. of concomitant AEDs 2.09 
Most frequently used concomitant AEDs at baseline
Carbamazepine 53.0%
Clobazam 38.1%
Phenytoin 24.4%
Oxcarbazepine 16.7%
Valproic acid 21.4%using the International League Against Epilepsy (ILAE) classiﬁca-
tion. Treatmentwas evaluated every 6months for each drug. Mood
disorders due to the use of AEDs were classiﬁed into activating and
sedating effects, with the former leading to aggression, hyperirrit-
ability, and agitation, and the latter leading to apathy and
depression.9,10 Data forms were entered into a computerized
database for analysis. Statistical analysiswas performed using SPSS
15.0 for Windows. Retention rates were calculated by using
Kaplan–Meier survival analysis,11 and comparisons between the
retention curves were analyzed using log-rank tests. Other
comparisons between the drugs were analyzed using non-
parametric statistics, Pearson X2.
3. Results
One hundred of 1166 patients had the drug of interest
prescribed initially elsewhere or data were lacking. Therefore,
data from 1066 patients were included in the analysis: 429 for
TPM, 336 for LTG, and 301 for LEV. The main characteristics of
patients are given in Table 1. Populations representing LTG, LEV,
and TPM were similar for the most important demographic and
clinical variables and represent the typical group of refractory
patients referred to a tertiary epilepsy centre.
Kaplan–Meier survival analysis, shown by Fig. 1, revealed
signiﬁcant differences between the drugs. Estimated retention
rates of 75.2% (LTG), 65.6% (LEV), and 51.7% (TPM)were reported at
1 year (LTG vs. LEV at p = 0.008; LTG vs. TPM at p < 0.001; LEV vs.
TPM at p = 0.002). Retention at 2 years had decreased to 69.2% for
LTG, 45.8% for LEV, and 38.3% for TPM (LTG vs. LEV at p < 0.001;
LTG vs. TPM at p < 0.001; LEV vs. TPM at p = 0.005).
Fig. 2 shows the percentages of patients that are free of seizures
from baseline. Seizure freedom rates were lowest for LTG and
highest for LEV at all assessment points. No statistically signiﬁcant
differences between the seizure freedom rates could be identiﬁed.LEV TPM
301 429
16.4 32.5  16.8 34.9  8.6
1–75 1–73
18 19.9% < 18 24.5% < 18
6 156/145 204/225
20.6 50.5  21.6 54.0  26.6
.8%) 217 (72.1%) 323 (75.3%)
8%) 54 (17.9%) 86 (20.1%)
) 16 (5.4%) 10 (2.3%)
1%) 14 (4.6%) 10 (2.3%)
.0%) 243 (80.7%) 352 (82.1%)
.2%) 138 (45.8%) 209 (48.7%)
%) 19 (6.3%) 19 (4.4%)
7%) 28 (9.3%) 31 (7.2%)
11.2 11.7  11.7 9.7  11.1
14.1 21.3  12.9 21.1  13.4
.4%) 98 (32.6%) 158 (36.8%)
17.3% 18.9%
31.9% 36.4%
0.847 2.16  0.827 2.04  0.779
39.9% 44.8%
37.6% 34.3%
15.6% 19.3%
16.3% 14.5%
19.3% 18.4%
Fig. 1. Estimated retention rates by Kaplan–Meier survival analysis; comparison
between LTG, LEV, and TPM.
Fig. 2. Long-term seizure remission from baseline; comparison between LTG, LEV,
and TPM.
Fig. 3. Percentage of total study population in which adverse events played a role in
drug discontinuation; comparison between LTG, LEV, and TPM.
Table 2
Reported side effects in patients who discontinued drug treatment.a.
LTG LEV TPM
Dizziness (14.9%) Mood disorders"b (13.8%) Mental slowing (27.8%)
Mood disorders" (11.7%) Tiredness (13.8%) Dysphasiac (15.0%)
Rash (10.6%) Mood disorders#d (13.1%) Mood disorders" (13.2%)
Sleeplessness (7.4%) Sleepiness (8.5%) Gastrointestinal (10.6%)
Sleepiness (6.4%) Paresthesia (7.5%)
Appetite loss (7.0%)
Skin (6.6%)
Weight loss (6.2%)
Mood disorders# (5.7%)
Headache (5.7%)
Dizziness (5.3%)
a Only side effects that occurred in >5% of patients are reported in the table.
b Mood disorders": agitation, aggression, hyperirritability.
c Dysphasia: word-ﬁnding difﬁculties.
d Mood disorders#: depression, apathy.
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429 patients (35.9%) on TPM (Fig. 3). Signiﬁcantly less patients
discontinued drug treatment because of adverse events in the
other populations: 52 of 336 patients (15.5%) on LTG (p < 0.001)
and 68 of 301 patients (22.5%) on LEV (p < 0.001). The difference
between LTG and LEV is also signiﬁcant (p = 0.028).
The most frequently reported side effects in patients who
discontinued treatment are listed in Table 2. Effects on mood and
general CNS-effects (dizziness, tiredness, sleepiness) were com-
mon side effects at time of discontinuation in patients on LTG, LEV,
and TPM. In patients on TPM, the neurocognitive side effects likemental slowing and dysphasia were most important and
contributed to almost half of patients in discontinuing treatment.
Rash played a role in drug discontinuation in both the LTG and TPM
study populations.
The most frequently reported side effects per assessment point
are shown in Table 3. Similarly, effects on mood and general CNS-
effects are common side effects in patients on LTG and LEV, and
neurocognitive side effects are most prevalent in patients on TPM.
A positive effect on behaviour is most frequently noted in patients
on LTG. Improved alertness, emotional stability, and reduced
irritability were frequently noted. This effect is seen in a
substantial number of patients on LEV only in the ﬁrst 6 months,
and not at all in patients on TPM.
4. Discussion
This audit compared the use of LTG, LEV, and TPM, presently
three of the most commonly prescribed new AEDs in chronic
epilepsy. The study population consisted of patients with chronic
refractory epilepsy referred to a single tertiary epilepsy centre. The
added value of this study is due to the direct comparison of the
long-term performance of LTG, LEV, and TPM including seizure
freedom rates and safety issues, the large number of patients
included (n = 336 for LTG; n = 301 for LEV; n = 429 for TPM), the
long period of evaluation (24months), and the low risk of selection
bias by the inclusion of all patients who were started on LTG, LEV,
or TPM in a certain period. This is illustrated by the characteristics
of our study population, speciﬁcally by awide age range and a large
number of children (22%) and mentally retarded (33%). The
patients on each drug did not differ on any of the clinical or
demographical variables, which allows us to compare LTG, LEV,
and TPM and to assume that differences in outcome are drug-
related.
Many studies have been done on individual new AEDs as add-
on treatment. However, few compare these new AEDs with each
other. Ideally, neurologists make treatment decisions based on
results from long-term randomized controlled trials that make
head-to-head comparisons. These trials are rarely performed
because of speciﬁc reasons.12 Therefore, results from long-term
observational studies become increasingly more important, since
these studies give clinicians insight in the long-term performance
of new AEDs in terms of retention rate, seizure control, and safety
proﬁle.
Oneway to compare the long-term performance of newAEDs in
observational studies is to evaluate retention rates. Retention rate
is considered to be a composite measure of drug efﬁcacy and drug
safety and expresses the willingness of patients to continue drug
Table 3
Most frequently reported side effects.a.
LTG LEV TPM
6 months Positive behaviourb (17.2%) Mood disorders"c (8.1%) Mental slowing (13.8%)
Dizziness (11.2%) Tiredness (7.4%) Dysphasiad (6.6%)
Gastrointestinal (5.7%) Positive behaviour (7.4%) Weight loss (5.2%)
12 months Positive behaviour (9.1%) Mood disorders" (5.2%) Mental slowing (13.6%)
Dizziness (6.9%) Dysphasia (5.7%)
18 months Positive behaviour (8.8%) Mood disorders" (10.6%) Mental slowing (8.1%)
Dizziness (8.8%) Tiredness (6.4%) Dysphasia (6.5%)
Mood disorders" (5.7%)
24 months Positive behaviour (7.2%) (Number of patients too small to provide meaningful data) Urogenitale (5.6%)
Dizziness (5.1%)
a Only side effects that occurred in >5% of the patients are reported in the table.
b Positive behaviour: improved alertness, emotional stability, reduced irritability, etc.
c Mood disorders": agitation, aggression, hyperirritability.
d Dysphasia: word-ﬁnding difﬁculties.
e Urogenital complaints: impotence, amenorrhea, micturation problems, etc.
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an AED. In our study, retention rate at 2 yearswas highestwith LTG
(69.2%), followed by LEV (45.8%), and TPM (38.3%). Chung et al.
showed similar 2-year retention rates of 74.1% for LTG, 53.6% for
LEV, and 44.2% for TPM (5). In addition, a study executed in a
residential community of adults with chronic epilepsy and
learning disability found a higher retention rate at 5 years in
patients on LTG (52%) compared to patients on LEV (32%) and TPM
(28%). However, 2-year retention rates for LTG and LEV were
similar (57% and 56%, respectively).13
Contrary to those studies and most other published follow-up
studies, we obtained estimates of the proportion of patients with
complete seizure control for at least 6 months. This is relevant,
since these ﬁgures provide clinically themostmeaningful data for
predicting the long-term efﬁcacy of an AED.14 This is especially
important since in this study the category of patients were
regarded as drug resistant and the new AEDs have substantially
added value in this population. Surprisingly, higher seizure
freedom rates were not associated with higher retention rates.
Retention rate for LTG was highest, whereas seizure freedom
rates, although not statistically signiﬁcant, were lowest. Long-
term retention for TPM was dramatically lower than for LTG,
whereas seizure freedom rates were higher. This suggests that the
impact of the achievement of seizure remission on long-term
retention is considered less important. Moreover, it should be
noted that not all patients who continue on therapy do so because
of improvement in seizure frequency. Some patients continued
drug treatment while experiencing even a higher seizure
frequency.
As a marker of tolerability we used the percentage of patients
withdrawing drug treatment because of adverse events. TPM was
by far the least well-tolerated drug, followed by LEV, and LTG. AED-
speciﬁc adverse events that often led to discontinuation of drug
treatment were mental slowing and dysphasia in patients on TPM,
mood disorders in patients on LEV, and rash in patients on LTG, as
previously reported in other studies.8,13,15–18 As expected, we
found a correlation between side effects and long-term retention:
the higher the percentages of patients withdrawing because of
adverse events, the lower the retention rate.
Several ﬁndings with respect to retention rates were note-
worthy in our study. Firstly, retention rates could have been
inﬂuenced by the sequence in which LTG, LEV, and TPM were
marketed. Patients on drugs that were marketed ﬁrst could have
been withdrawn from treatment because of the availability of a
new AED. On the other hand, drugs that were marketed later could
have been tested in a more refractory population.Secondly, if patients did stop taking the audit drug, they were
most likely to do this in the ﬁrst 6–12 months, mostly due to
adverse events. This implicates that surviving the toxic effects of an
AED in the early stage is a good indicator of long-term retention.
This is also mentioned by other studies reporting continuation
rates of about 90% for LTG, LEV, and TPM after surviving the initial
stage of AED introduction.8,19
Thirdly, cognitive impairment is a common side effect in
patients using AEDs.20 Across studies, LTG adjunctive therapy did
not worsen, and sometimes improved, pre-existing cognitive
dysfunction in patientswith epilepsy.21 In one study, only 11 of 81
patients (13.6%) achieved a 50% reduction in seizure frequency on
LTG, whereas more than 50% chose to continue LTG therapy,
indicating that other factors inﬂuenced their decision.22 In
contrast, TPM has been associated with cognitive impairment,
particularly in verbal function, memory, and attention in patients
with epilepsy.15,23,24 In our study, almost half of patients on TPM
discontinued treatment because of the drug’s negative effects on
cognition. However, patients on LTG frequently experienced a
positive effect on cognition. Patients were less irritable, more
alert, and emotionally stable. We think that the side effect
proﬁle, and especially the impact of an AED on cognitive function,
is the main determinant of retention rate. Therefore, effects on
cognition constitute a key consideration in selecting antiepileptic
drugs.
To conclude: the new AEDs have substantially added value in
the group of drug resistant epilepsy patients. In addition a drug
that is only modestly efﬁcacious but has a favourable safety proﬁle
may seem better than a drug that is more efﬁcacious but produces
clinically meaningful adverse events. Therefore, a drug’s retention
rate is mainly determined by its side effect proﬁle. The gain in
quality of life after drug initiation determines the continuation rate
of an individual AED, with the effects on cognition being far more
important than seizure control. As a consequence, retention rate
was highest for LTG and lowest for TPM. Intermediate retention
rates were seen with LEV use.
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